Affordable Access

Perioperative therapy for locoregional nonsmall-cell lung cancer.

Authors
  • Takita, H
Type
Published Article
Journal
Journal of surgical oncology
Publication Date
May 01, 1996
Volume
62
Issue
1
Pages
65–74
Identifiers
PMID: 8618405
Source
Medline
License
Unknown

Abstract

Surgical therapy remains the treatment of choice for resectable nonsmall-cell lung cancer (NSCLC). However, the 5-year survival results of surgical therapy is 40-70%, which is far from acceptable. In this report, past results of perioperative therapies were reviewed to identify the future direction of effort in improving the therapy of NSCLC. Two perioperative modes of treatment that may possibly improve postsurgical survival were identified, i.e., neoadjuvant chemotherapy for resectable NSCLC and postoperative specific active immunotherapy.

Report this publication

Statistics

Seen <100 times